{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:45:46Z","timestamp":1773391546093,"version":"3.50.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["PID2021-128891OB-I00"],"award-info":[{"award-number":["PID2021-128891OB-I00"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["PID2019-107160RB-I00"],"award-info":[{"award-number":["PID2019-107160RB-I00"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["PLEC2021\u2013007664"],"award-info":[{"award-number":["PLEC2021\u2013007664"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NextGenerationEU","award":["MCIN\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MCIN\/AEI\/10.13039\/501100011033"]}]},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/11\/00411"],"award-info":[{"award-number":["CB16\/11\/00411"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0011\/018"],"award-info":[{"award-number":["RD16\/0011\/018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Generalitat of Catalunya-Secretaria d\u2019Universitats i Recerca del Departament d\u2019Economia i Coneixement de la Generalitat","award":["2017SGR1480"],"award-info":[{"award-number":["2017SGR1480"]}]},{"name":"Generalitat of Catalunya-Secretaria d\u2019Universitats i Recerca del Departament d\u2019Economia i Coneixement de la Generalitat","award":["2016PROD00043"],"award-info":[{"award-number":["2016PROD00043"]}]},{"name":"Generalitat de Catalu\u00f1a, and Fundaci\u00f3n Investigaci\u00f3n Cardiovascular"},{"name":"Fundaci\u00f3n Jes\u00fas Serra"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The ecto\u2013nucleoside triphosphate diphosphohydrolases of the CD39 family degrade ATP and ADP into AMP, which is converted into adenosine by the extracellular CD73\/ecto-5-nucleotidase. This pathway has been explored in antithrombotic treatments but little in myocardial protection. We have investigated whether the administration of solCD39L3 (AZD3366) confers additional cardioprotection to that of ticagrelor alone in a pre-clinical model of myocardial infarction (MI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ticagrelor-treated pigs underwent balloon-induced MI (90\u2005min) and, before reperfusion, received intravenously either vehicle, 1\u2005mg\/kg AZD3366 or 3\u2005mg\/kg AZD3366. All animals received ticagrelor twice daily for 42 days. A non-treated MI group was run as a control. Serial cardiac magnetic resonance (baseline, Day 3 and Day 42 post-MI), light transmittance aggregometry, bleeding time, and histological and molecular analyses were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ticagrelor reduced oedema formation and infarct size at Day 3 post-MI vs. controls. A 3\u2005mg\/kg AZD3366 provided an additional 45% reduction in oedema and infarct size compared with ticagrelor and a 70% reduction vs. controls (P &amp;lt; .05). At Day 42, infarct size declined in all ticagrelor-administered pigs, particularly in 3\u2005mg\/kg AZD3366-treated pigs (P &amp;lt; .05). Left ventricular ejection fraction was diminished at Day 3 in placebo pigs and worsened at Day 42, whereas it remained unaltered in ticagrelor \u00b1 AZD3366-administered animals. Pigs administered with 3\u2005mg\/kg AZD3366 displayed higher left ventricular ejection fraction upon dobutamine stress at Day 3 and minimal dysfunctional segmental contraction at Day 42 (\u03c72P &amp;lt; .05 vs. all). Cardiac and systemic molecular readouts supported these benefits. Interestingly, AZD3366 abolished ADP-induced light transmittance aggregometry without affecting bleeding time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Infusion of AZD3366 on top of ticagrelor leads to enhanced cardioprotection compared with ticagrelor alone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae107","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T05:16:24Z","timestamp":1710479784000},"page":"1553-1567","source":"Crossref","is-referenced-by-count":8,"title":["Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-8873","authenticated-orcid":false,"given":"Gemma","family":"Vilahur","sequence":"first","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Radike","sequence":"additional","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"},{"name":"Radiology Department, Liverpool Heart and Chest Hospital NHS Foundation Trust , Liverpool , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Sutelman","sequence":"additional","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumaya","family":"Ben-Aicha","sequence":"additional","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Casan\u00ed","sequence":"additional","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hovdal","sequence":"additional","affiliation":[{"name":"DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L","family":"Ongstad","sequence":"additional","affiliation":[{"name":"Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Gabrielsen","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Radiology Department, Hospital Josep Trueta , Girona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Fjellstr\u00f6m","sequence":"additional","affiliation":[{"name":"Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2459","authenticated-orcid":false,"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[{"name":"Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , C\/Sant Antoni M\u00aa Claret 167, Barcelona 08025 , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2024050717420923800_ehae107-B1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1074248412467692","article-title":"Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts","volume":"18","author":"Yang","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2024050717420923800_ehae107-B2","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jacc.2017.02.034","article-title":"Ticagrelor versus clopidogrel on myocardial infarct size in patients undergoing primary percutaneous coronary intervention","volume":"69","author":"Kim","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.jcin.2020.08.007","article-title":"Effect of ticagrelor on left ventricular remodeling in patients with ST-segment elevation myocardial infarction (HEALING-AMI)","volume":"13","author":"Park","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2024050717420923800_ehae107-B4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00395-021-00870-y","article-title":"Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction","volume":"116","author":"Hjortbak","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"2024050717420923800_ehae107-B5","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.116.024014","article-title":"Protective effects of ticagrelor on myocardial injury after infarction","volume":"134","author":"Vilahur","year":"2016","journal-title":"Circulation"},{"key":"2024050717420923800_ehae107-B6","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1161\/CIRCULATIONAHA.117.027588","article-title":"Response by Vilahur, et al to letters regarding article, \u201cprotective effects of ticagrelor on myocardial injury after infarction\u201d","volume":"135","author":"Vilahur","year":"2017","journal-title":"Circulation"},{"key":"2024050717420923800_ehae107-B7","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/ATVBAHA.114.304002","article-title":"Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect","volume":"34","author":"Nanhwan","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024050717420923800_ehae107-B8","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/cvr\/cvy201","article-title":"P2y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs","volume":"114","author":"Vilahur","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2024050717420923800_ehae107-B9","doi-asserted-by":"crossref","first-page":"9219825","DOI":"10.1155\/2020\/9219825","article-title":"Ticagrelor conditioning effects are not additive to cardioprotection induced by direct NLRP3 inflammasome inhibition: role of RISK, NLRP3, and Redox Cascades","volume":"2020","author":"Penna","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"2024050717420923800_ehae107-B10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10557-022-07345-9","article-title":"Platelet-mediated transfer of cardioprotection by remote ischemic conditioning and its abrogation by aspirin but not by ticagrelor","volume":"37","author":"Lieder","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024050717420923800_ehae107-B11","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.107.690180","article-title":"CD39\/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia\/reperfusion injury","volume":"116","author":"Ko\u0308hler","year":"2007","journal-title":"Circulation"},{"key":"2024050717420923800_ehae107-B12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10557-015-6633-2","article-title":"Cangrelor-mediated cardioprotection requires platelets and sphingosine phosphorylation","volume":"30","author":"Cohen","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024050717420923800_ehae107-B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07373-5","article-title":"A comprehensive review of the pleiotropic effects of ticagrelor","author":"Triska","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024050717420923800_ehae107-B14","doi-asserted-by":"crossref","first-page":"33116","DOI":"10.1074\/jbc.271.51.33116","article-title":"Identification and characterization of CD39\/vascular ATP diphosphohydrolase","volume":"271","author":"Kaczmarek","year":"1996","journal-title":"J Biol Chem"},{"key":"2024050717420923800_ehae107-B15","doi-asserted-by":"crossref","first-page":"H1797","DOI":"10.1152\/ajpheart.00407.2003","article-title":"Acute adenosinergic cardioprotection in ischemic-reperfused hearts","volume":"285","author":"Headrick","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024050717420923800_ehae107-B16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00374659","article-title":"Involvement of endogenous adenosine in ischaemic preconditioning in swine","volume":"430","author":"Schulz","year":"1995","journal-title":"Pflugers Arch"},{"key":"2024050717420923800_ehae107-B17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.106.669697","article-title":"Cardioprotection by ecto-5\u2032-nucleotidase (CD73) and A2B adenosine receptors","volume":"115","author":"Eckle","year":"2007","journal-title":"Circulation"},{"key":"2024050717420923800_ehae107-B18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood.V104.11.530.530","article-title":"Antithrombotic activity of a novel engineered human apyrase. Enzymatic profile, ex vivo and in vivo properties","volume":"104","author":"Jeong","year":"2004","journal-title":"Blood"},{"key":"2024050717420923800_ehae107-B19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jth.13621","article-title":"Recombinant soluble apyrase APT102 inhibits thrombosis and intimal hyperplasia in vein grafts without adversely affecting hemostasis or re-endothelialization","volume":"15","author":"Ji","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2024050717420923800_ehae107-B20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.healun.2014.09.034","article-title":"Human recombinant apyrase therapy protects against canine pulmonary ischemia-reperfusion injury","volume":"34","author":"Ibrahim","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"2024050717420923800_ehae107-B21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejphar.2014.05.052","article-title":"Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats","volume":"738","author":"Tan","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2024050717420923800_ehae107-B22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3348\/kjr.2019.0853","article-title":"Human recombinant apyrase therapy protects against myocardial ischemia\/reperfusion injury and preserves left ventricular systolic function in rats, as evaluated by 7T cardiovascular magnetic resonance imaging","volume":"21","author":"Xu","year":"2020","journal-title":"Korean J Radiol"},{"key":"2024050717420923800_ehae107-B23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10557-022-07329-9","article-title":"Recombinant apyrase AZD3366 against myocardial reperfusion injury","volume":"37","author":"Birnbaum","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024050717420923800_ehae107-B24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia-reperfusion injury and cardioprotection in perspective","volume":"17","author":"Heusch","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2024050717420923800_ehae107-B25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2006.07.003","article-title":"ACCF\/ACR\/SCCT\/SCMR\/ASNC\/NASCI\/SCAI\/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology","volume":"48","author":"Hendel","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","article-title":"Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel","volume":"74","author":"Ibanez","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B27","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/bph.15178","article-title":"ARRIVE 2.0 and the British Journal of Pharmacology: updated guidance for 2020","volume":"177","author":"Lilley","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2024050717420923800_ehae107-B28","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2020.01.042","article-title":"Intravenous statin administration during myocardial infarction compared with oral post-infarct administration","volume":"75","author":"Mendieta","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jacc.2019.05.020","article-title":"Intravenous statin administration during ischemia exerts cardioprotective effects","volume":"74","author":"Mendieta","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B30","doi-asserted-by":"crossref","first-page":"e13860","DOI":"10.1111\/eci.13860","article-title":"A comprehensive and longitudinal cardiac magnetic resonance imaging study of the impact of coronary ischemia duration on myocardial damage in a highly translatable animal model","volume":"53","author":"Radike","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"2024050717420923800_ehae107-B31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.recesp.2022.06.007","article-title":"Comparison of two cardiac magnetic resonance imaging postprocessing software tools in a pig model of myocardial infarction","volume":"76","author":"Radike","year":"2023","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2024050717420923800_ehae107-B32","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.jacc.2015.08.901","article-title":"Hypercholesterolemia abolishes high-density lipoprotein-related cardioprotective effects in the setting of myocardial infarction","volume":"66","author":"Vilahur","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00395-021-00893-5","article-title":"IMproving preclinical assessment of cardioprotective therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST action","volume":"116","author":"Lecour","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"2024050717420923800_ehae107-B34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/cvr\/cvu225","article-title":"ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies","volume":"104","author":"Lecour","year":"2014","journal-title":"Cardiovasc Res"},{"key":"2024050717420923800_ehae107-B35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCRESAHA.119.315344","article-title":"Optimized treatment of ST-elevation myocardial infarction","volume":"125","author":"Niccoli","year":"2019","journal-title":"Circ Res"},{"key":"2024050717420923800_ehae107-B36","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/biom10050740","article-title":"Ticagrelor prevents endothelial cell apoptosis through the adenosine signalling pathway in the early stages of hypoxia","volume":"10","author":"Feliu","year":"2020","journal-title":"Biomolecules"},{"key":"2024050717420923800_ehae107-B37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1161\/CIRCRESAHA.116.305348","article-title":"Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning","volume":"116","author":"Heusch","year":"2015","journal-title":"Circ Res"},{"key":"2024050717420923800_ehae107-B38","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.jacc.2012.03.026","article-title":"Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction","volume":"59","author":"Thuny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B39","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0003-4975(99)01025-5","article-title":"Prime causes of rapid cardiomyocyte death during reperfusion","volume":"68","author":"Piper","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"2024050717420923800_ehae107-B40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd2638","article-title":"Adenosine receptors: therapeutic aspects for inflammatory and immune diseases","volume":"7","author":"Hask\u00f3","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"2024050717420923800_ehae107-B41","doi-asserted-by":"crossref","first-page":"C589","DOI":"10.1152\/ajpcell.00235.2017","article-title":"Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis","volume":"314","author":"Alsaffar","year":"2018","journal-title":"Am J Physiol Cell Physiol"},{"key":"2024050717420923800_ehae107-B42","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jacc.2015.02.032","article-title":"Evolving therapies for myocardial ischemia\/reperfusion injury","volume":"65","author":"Ibanez","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024050717420923800_ehae107-B43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2015.09.005","article-title":"Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials","volume":"202","author":"Bulluck","year":"2016","journal-title":"Int J Cardiol"},{"key":"2024050717420923800_ehae107-B44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/eurheartj\/ehq492","article-title":"High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction","volume":"32","author":"Desmet","year":"2011","journal-title":"Eur Heart J"},{"key":"2024050717420923800_ehae107-B45","first-page":"1646","article-title":"Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non\u2013ST-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial","volume":"10","author":"Jeong","year":"2017","journal-title":"JACC: Cardiovasc Interv"},{"key":"2024050717420923800_ehae107-B46","first-page":"1576","article-title":"Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers","volume":"11","author":"Ariotti","year":"2018","journal-title":"JACC: Cardiovasc Interv"},{"key":"2024050717420923800_ehae107-B47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00395-023-00993-4","article-title":"No robust reduction of infarct size and no-reflow by metoprolol pretreatment in adult Gottingen minipigs","volume":"118","author":"Kleinbongard","year":"2023","journal-title":"Basic Res Cardiol"},{"key":"2024050717420923800_ehae107-B48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1160\/TH07-11-0673","article-title":"P2 receptors, platelet function and pharmacological implications","volume":"99","author":"Gachet","year":"2008","journal-title":"Thromb Haemost"},{"key":"2024050717420923800_ehae107-B49","first-page":"397","article-title":"Novel antithrombotic agents in ischemic cardiovascular disease: progress in the search for the optimal treatment","volume":"9","author":"Barriuso","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"2024050717420923800_ehae107-B50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00395-021-00896-2","article-title":"Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2\/ERIC-PPCI CMR substudy","volume":"116","author":"Francis","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"2024050717420923800_ehae107-B51","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/eurheartj\/ehp113","article-title":"Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for &lt;12 h vs. 12\u201372 h","volume":"30","author":"Busk","year":"2009","journal-title":"Eur Heart J"},{"key":"2024050717420923800_ehae107-B52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yjmcc.2011.03.003","article-title":"A small molecule AMPK activator protects the heart against ischemia-reperfusion injury","volume":"51","author":"Kim","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"2024050717420923800_ehae107-B53","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1097\/CCM.0b013e31829866dc","article-title":"Connection between cardiac vascular permeability, myocardial edema, and inflammation during sepsis: role of the alpha1AMP-activated protein kinase isoform","volume":"41","author":"Castanares-Zapatero","year":"2013","journal-title":"Crit Care Med"},{"key":"2024050717420923800_ehae107-B54","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"2024050717420923800_ehae107-B55","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10557-022-07327-x","article-title":"Do we really need aspirin loading for STEMI?","volume":"36","author":"Ye","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024050717420923800_ehae107-B56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2459\/JCM.0000000000001345","article-title":"Efficacy of ticagrelor compared to clopidogrel in improving endothelial function in patients with coronary artery disease: a systematic review","volume":"23","author":"Albadrani","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2024050717420923800_ehae107-B57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.atherosclerosis.2012.07.003","article-title":"Infiltrated cardiac lipids impair myofibroblast-induced healing of the myocardial scar post-myocardial infarction","volume":"224","author":"Vilahur","year":"2012","journal-title":"Atherosclerosis"},{"key":"2024050717420923800_ehae107-B58","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1111\/bph.14931","article-title":"Hyperlipidaemia and cardioprotection: animal models for translational studies","volume":"177","author":"Andreadou","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2024050717420923800_ehae107-B59","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1093\/cvr\/cvad034","article-title":"A primordial obstacle in cardioprotection: the answer resides in our genes","volume":"119","author":"Vilahur","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2024050717420923800_ehae107-B60","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/eurheartj\/ehad160","article-title":"Primordial non-responsiveness: a neglected obstacle to cardioprotection","volume":"44","author":"Heusch","year":"2023","journal-title":"Eur Heart J"},{"key":"2024050717420923800_ehae107-B61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cvr\/cvac062","article-title":"No sex-related differences in infarct size, no-reflow, and protection by ischaemic pre-conditioning in Gottingen minipigs","volume":"119","author":"Kleinbongard","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2024050717420923800_ehae107-B62","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.CIR.0000121424.76486.20","article-title":"Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts","volume":"109","author":"De Luca","year":"2004","journal-title":"Circulation"},{"key":"2024050717420923800_ehae107-B63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00395-019-0760-z","article-title":"Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia","volume":"115","author":"Mendieta","year":"2019","journal-title":"Basic Res Cardiol"},{"key":"2024050717420923800_ehae107-B64","doi-asserted-by":"crossref","first-page":"A13097","DOI":"10.1161\/circ.146.suppl_1.13097","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AZD3366 alone and in combination with aspirin and ticagrelor in healthy subjects","volume":"146","author":"Kardassis","year":"2022","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/17\/1553\/57443228\/ehae107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/17\/1553\/57443228\/ehae107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T17:43:51Z","timestamp":1715103831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/17\/1553\/7629191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":64,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae107","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,3,15]]}}}